Halozyme Therapeutics Receives 'Hold' Rating from Analysts

Analysts split on the biopharmaceutical company's future performance

Mar. 14, 2026 at 6:45am

Got story updates? Submit your updates here. ›

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has received an average 'Hold' rating from the twelve analysts currently covering the company, according to a MarketBeat.com report. One analyst has rated the stock as a 'Sell', five have issued 'Hold' ratings, and six have given 'Buy' recommendations. The average 12-month price target among the analysts is $78.56.

Why it matters

Halozyme Therapeutics is a biopharmaceutical company focused on developing novel drug-delivery technologies. The mixed analyst ratings and price targets suggest uncertainty around the company's future performance and growth potential, which could impact investor sentiment and the stock price.

The details

The analysts' ratings and price targets for Halozyme Therapeutics are based on the company's financial results, pipeline progress, and competitive landscape. Some analysts see potential upside in the stock, while others are more cautious due to factors such as valuation and market competition.

  • Halozyme Therapeutics released its latest quarterly earnings report on February 17, 2026.

The players

Halozyme Therapeutics, Inc.

A biopharmaceutical company headquartered in San Diego, California that specializes in the development and commercialization of novel drug-delivery technologies.

MarketBeat.com

A financial media company that provides stock market news, data, and analysis.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The mixed analyst ratings on Halozyme Therapeutics highlight the uncertainty surrounding the company's future prospects, underscoring the need for investors to closely monitor the company's financial performance, pipeline progress, and competitive landscape as they evaluate the stock.